Standard Process Partners with Pathway OME To Offer Genetics and AI Services – A Breakthrough in Personalized Wellness

San Diego, CA (Sept 20, 2018) – Standard Process and Pathway OME have announced a partnership to assist patients and physicians with personal wellness and healthcare. Pathway OME is the leading genetic wellness company for nutrition, exercise, skincare and Artificial Intelligence (AI), used to help guide lifestyle, diet and nutritional supplement decisions to improve the overall health and wellbeing of patients.

Pathway OME FIT and SkinFIT tests provide evidence-based, personalized, actionable information and product recommendations, based on patients’ genetic results that helps them adjust their lifestyle, diet, habits and activities to improve their overall quality of life. Each test analyzes variations in 70+ key genes in many domains of health: Eating Behaviors, Diets and Diet plans, Lipid and Sugar metabolism, Skin Photoaging and Hydration, Micronutrients, Inflammation and Exercise.

Testing with Pathway OME is simple and quick. A DNA sample is collected by a cheek swab and the results (including a diet plan) are returned to the ordering clinician or user in 10 days or less.

Healthcare practitioners can then use the FIT and SkinFIT test results to create personalized wellness plans using Standard Process products.

“This is a very exciting step that allows us to provide practitioners and patients with advanced insight into a patient’s metabolism,” says John Troup, PhD, Standard Process Vice President of Clinical Science, Education & Innovation. “With the genetic results and AI analysis from Pathway OME, we will be able to bridge the gap between individual metabolism and healthcare while providing more personalized nutritional support. This is a perfect “fit” for our commitment to be the preferred practitioner partner in the delivery of advanced nutrition therapy programs, dietetics, and expertise. As we support practitioners of all specialties across the integrative and functional medicine categories, we prioritize personalized nutrition therapy based on sound evidence for improved personalized outcomes. We chose Pathway OME because for a decade, they have conducted a huge number of genetic tests for patients in 44 different countries and developed FIT and SkinFIT based on their expertise in obesity, diabetes, skincare and cardiometabolic issues and their belief in providing actionable product recommendations.”

“We know Standard Process as the visionary leader in clinical nutrition therapies and personalization based on whole food nutrition solutions.,” says Dr. Michael Nova, Pathway OME Chief Innovation Officer and Founder. “We are proud that FIT and SkinFIT will now be able to help Standard Process healthcare practitioners and patients identify variations in gene networks that influence health and wellness.”

To learn more about FIT and SkinFIT, healthcare providers and patients can visit www.pathway.com

Pathway Genomics
Since its founding in 2009, Pathway Genomics has become known for its dedication to innovation – making it a leader in the commercial personalized health and wellness industries. Focusing on providing users with the most validated and personalized healthcare information delivered to any device, the company’s program with IBM data is the first of its kind to merge artificial intelligence (AI) and deep learning with precision medicine, applicable to both consumers and providers.

United Crest Healthcare Signed A Deal To Provide Pathway’s DNA Tests In Asia And Russia

Kuala Lumpur–United Crest Healthcare (“United”) announced announced on December 18, 2017 that United has signed an agreement with Pathway Genomics Corporation (“Pathway”) to provide DNA tests in the Asia-Pacific region. Pathway, a CLIA certified and CAP accredited clinical laboratory based in San Diego, California, specializes in genetic testing and analysis. In addition to the ASEAN countries, United will also offer these services in China, Russia, and Taiwan.

Pathway Genomics and Salud Interactiva announce partnership to bring advanced clinical genetic testing to millions in Mexico

SAN DIEGO, CA —-Pathway Genomics and Salud Interactiva, a company backed by Sinca Inbursa, today announced a partnership that will make Pathway’s wide range of clinical genetic testing with advanced Artificial Intelligence analysis available to millions of Salud Interactiva’s users in Mexico. Salud Interactiva, a leading third party administrator offering health services in 3 countries, has a network of over 6 million users and associations comprised of insurance companies, private clinics (e.g. Bio Clinique), and other corporate partners.

Pathway Genomics to Present at the 2017 UBS Global Healthcare Conference

SAN DIEGO–(BUSINESS WIRE)–Pathway Genomics, an innovative commercial-stage genomics company, announced today that Dr. Michael Nova, Chief Innovation Officer, and Kamal Adawi, Chief Financial Officer, will present at the 2017 UBS Global Healthcare Conference. This event will be held at the Grand Hyatt in New York City on Monday, May 22nd through May 24th. Pathway’s presentation will take place Monday, May 22, 2017 at 3:00 p.m. EDT. The presentation will be available on Pathway.com.

Pathway Genomics to participate in NASDAQ Fit Week

San Diego, CA – (BUSINESS WIRE) – January 2, 2017 — Pathway Genomics, an innovative commercial-stage genomics company, announced today that they will be participating in the 7th annual NASDAQ Fit Week. PathwayFit®, their test that assesses 80 genetic markers to help personalize and optimize diet, nutrition, metabolic health and exercise regimes, will be featured at Fit Week. As part of the event, Pathway will be offering PathwayFit® for a special price of $199 during the month of January and will also kick off the “This Is My Pathway” video contest to help create awareness about making informed, proactive lifestyle decisions.

Pathway Genomics to Present & Exhibit at The 24th Annual World Congress on Anti-Aging Medicine

San Diego, CA – (BUSINESS WIRE) – December 8, 2016 —Pathway Genomics, an innovative commercial-stage genomics company, announced today that Dr. Michael Nova, Chief Innovation Officer, will present at the 24th Annual World Congress on Anti-Aging Medicine in Las Vegas, Nevada. Dr. Nova will present on Nutritional Genetics and Epigenetics in Diabetes and Obesity Management on Friday December 9th at 2:55pm in the Veronese Room (2503-4/2403-4) at the Venetian Hotel. Additionally, Pathway will be exhibiting at the conference in booth 3098.

Pathway Genomics’ Chief Financial Officer, Kamal Adawi, to present at the 28th Annual Piper Jaffray Healthcare Conference

San Diego, CA – (BUSINESS WIRE) – November 28, 2016 — Pathway Genomics, an innovative commercial-stage genomics company, announced today that Kamal Adawi, Chief Financial Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference. This conference will be held at The Lotte New York Palace in New York City on November 29th and 30th and the presentation will be made available on Pathway.com and Pathway’s social media.

“Pathway is honored to be a part of this important conference,” said Jim Plante, Founder & CEO. “We believe that proactively sharing healthcare industry knowledge helps us all gain a broader perspective that ultimately allows us to help more patients.”